NDC 24571-108

PRISMASOL BGK0/2.5

Calcium Chloride, Magnesium Chloride, Dextrose Monohydrate, Lactic Acid, Sodium Chloride And Sodium Bicarbonate

PRISMASOL BGK0/2.5 is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is Calcium Chloride; Dextrose Monohydrate; Lactic Acid, Unspecified Form; Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride.

• Product ID: 24571-108_250f27ad-a700-4fd7-aaeb-7ca4211c17d8
• NDC: 24571-108
• Product Type: Human Prescription Drug
• Proprietary Name: PRISMASOL BGK0/2.5
• Generic Name: Calcium Chloride, Magnesium Chloride, Dextrose Monohydrate, Lactic Acid, Sodium Chloride And Sodium Bicarbonate
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2006-10-25
• Marketing Category: NDA / NDA
• Application Number: NDA021703
• Labeler Name: Baxter Healthcare Corporation
• Substance Name: CALCIUM CHLORIDE; DEXTROSE MONOHYDRATE; LACTIC ACID, UNSPECIFIED FORM; MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
• Active Ingredient Strength: 4 g/L; g/L; g/L; g/L; g/L; g/L
• Pharm Classes: Acidifying Activity [MoA], Blood Coagulation Factor [EPC], Calcium [CS], Calculi Dissolution Agent [EPC], Cations, Divalent [CS], Increased Coagulation Factor Activity [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 24571-108-06

2 BAG in 1 CASE (24571-108-06) > 5 L in 1 BAG

• Marketing Start Date: 2006-10-25
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 24571-108-05 [24571010805]

PRISMASOL BGK0/2.5 INJECTION

• Marketing Category: NDA
• Application Number: NDA021703
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2006-10-25
• Marketing End Date: 2017-12-31

NDC 24571-108-06 [24571010806]

PRISMASOL BGK0/2.5 INJECTION

• Marketing Category: NDA
• Application Number: NDA021703
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2006-10-25

Drug Details

Active Ingredients

Ingredient	Strength
CALCIUM CHLORIDE	3.68 g/L

OpenFDA Data

• SPL SET ID: 7f675fee-8940-4ece-bb0c-75ac79d8708c
• Manufacturer:
  • Baxter Healthcare Corporation
• UNII:
  • 8MDF5V39QO
  • 33X04XA5AT
  • M4I0D6VV5M
  • 02F3473H9O
  • 94255I6E2T
  • 451W47IQ8X
  • LX22YL083G
  • 660YQ98I10

Pharmacological Class

• Blood Coagulation Factor [EPC]
• Increased Coagulation Factor Activity [PE]
• Calcium [CS]
• Cations
• Divalent [CS]
• Calculi Dissolution Agent [EPC]
• Magnesium Ion Exchange Activity [MoA]
• Osmotic Laxative [EPC]
• Osmotic Activity [MoA]
• Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
• Increased Large Intestinal Motility [PE]
• Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
• Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
• Osmotic Laxative [EPC]
• Increased Large Intestinal Motility [PE]
• Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
• Osmotic Activity [MoA]
• Osmotic Laxative [EPC]
• Increased Large Intestinal Motility [PE]
• Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
• Osmotic Activity [MoA]